FUTURE OF
TARGETED THERAPY
Several developments are already in Phase II/III trials -- close enough that they are relevant to current treatment decisions, either through trial access now or because knowing they are coming changes how to think about sequencing.
analyticsAt a Glance
- check_circleKRAS β previously "undruggable" β now has approved inhibitors (sotorasib, adagrasib) for KRAS G12C
- check_circleAntibody-drug conjugates (ADCs) combine targeted delivery with potent cytotoxic payloads
- check_circleDegrader drugs (PROTACs) offer a new mechanism for targeting previously resistant proteins
- check_circleCombination strategies to prevent or overcome acquired resistance are the major research focus
Near-Term Developments in Clinical Testing
These are active Phase I/II/III programmes with clinical data -- not theoretical futures.
Next-Generation KRAS Inhibitors
KRAS G12C was the first undruggable mutation to yield to targeted drugs. Second-generation G12C inhibitors with improved potency and CNS penetration are in Phase I/II. Inhibitors targeting KRAS G12D and G12V -- far more common mutations -- are entering clinical testing. This could meaningfully expand the targetable population in colorectal, lung, and pancreatic cancer.
PROTACs (Targeted Protein Degraders)
Rather than blocking a protein activity, degrader molecules mark it for cellular disposal entirely. Potentially effective against targets where blocking alone is insufficient. Early Phase I data in haematologic malignancies.
Bispecific Antibodies
Engineered to engage two targets simultaneously. Amivantamab (EGFR/MET bispecific) is already approved for EGFR exon 20 insertion NSCLC. Additional bispecifics in development for multiple cancer types including haematologic malignancies.
Next-Generation ADCs
Improved linker chemistry and payload selection producing ADCs with better therapeutic windows and reduced off-target toxicity. Multiple Phase III trials across breast, lung, gastric, and bladder cancers are ongoing.
Tumour-Agnostic Approvals
Regulatory agencies increasingly approve drugs based on molecular target rather than tumour location. Larotrectinib for NTRK fusions, pembrolizumab for MSI-H, and others have established this framework. More tumour-agnostic approvals are expected.
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Interested in Emerging Targeted Therapy Programmes?
CancerFax tracks active targeted therapy clinical trials and assesses whether emerging programmes are accessible for your specific mutation and diagnosis.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.